Pappagianis D
Department of Medical Microbiology and Immunology, School of Medicine, University of California, Davis 95616.
Am Rev Respir Dis. 1993 Sep;148(3):656-60. doi: 10.1164/ajrccm/148.3.656.
A vaccine consisting of formaldehyde-killed spherules of Coccidioides immitis, previously shown to provide protection against development of lethal coccidioidomycosis in laboratory animals, was evaluated in humans. This double blind "Phase 3" study, conducted during the period 1980 to 1985, involved 2,867 healthy subjects with no history of coccidioidomycosis and negative skin tests. Randomized into vaccine (n = 1,436) or placebo (n = 1,431) groups, the former received three intramuscular injections of 1.75 mg (dry weight) of spherules, the latter received three injections of sterile 0.85% NaCl solution. Compatible clinical presentation with cultural or serologic findings permitted detection of coccidioidomycosis. Of those receiving vaccine, nine developed coccidioidomycosis and nine additional were suspected of having the disease. Of the group receiving placebo, 12 developed coccidioidomycosis, and 13 additional were suspected of having the disease. All cases and suspected cases were mild. Under the conditions of this study, a slight but statistically insignificant reduction in the incidence of coccidioidomycosis was noted in the vaccinated group compared with that in the placebo group, and there was no discernible difference in severity of disease between these groups.
一种由经甲醛灭活的粗球孢子菌小球组成的疫苗,此前已证明其能在实验动物中预防致死性球孢子菌病的发生,现对其进行人体评估。这项双盲“3期”研究于1980年至1985年期间开展,涉及2867名无球孢子菌病病史且皮肤试验阴性的健康受试者。随机分为疫苗组(n = 1436)和安慰剂组(n = 1431),前者接受三次肌肉注射1.75毫克(干重)的小球,后者接受三次注射无菌0.85%氯化钠溶液。符合临床表现并伴有培养或血清学结果可确诊球孢子菌病。在接受疫苗的人群中,9人患球孢子菌病,另有9人疑似患有该病。在接受安慰剂的人群中,12人患球孢子菌病,另有13人疑似患有该病。所有病例和疑似病例均为轻症。在本研究条件下,与安慰剂组相比,接种疫苗组球孢子菌病发病率略有降低,但在统计学上无显著差异,且两组疾病严重程度无明显差异。